Cytokine therapies in Crohn's disease: Where are we now and where should we go?

Flavio Caprioli, Francesco Pallone, Giovanni Monteleone

Research output: Contribution to journalArticle

Abstract

In the gut of patients with Crohn's disease (CD), one of the major forms of inflammatory bowel diseases in humans, distinct subsets of T helper (Th) cells produce large amounts of cytokines, which are supposed to orchestrate the immuno-inflammatory process leading to the tissue damage. Indeed, cytokine blockers, including the three licensed anti- TNF-α and the neutralizing IL-12/p40 antibodies, have already been tested with success in CD. More than one third of patients do not respond to these treatments and response can wane with time. Moreover, blockade of such cytokines has been reported to associate with development of severe side effects and/or new immune-mediated pathologies. These findings and our better understanding of cytokine-associated effector pathways of tissue destruction suggest the necessity of novel cytokine-based therapies in CD.

Original languageEnglish
Pages (from-to)47-53
Number of pages7
JournalInflammation and Allergy - Drug Targets
Volume10
Issue number1
Publication statusPublished - 2011

Fingerprint

Crohn Disease
Cytokines
Therapeutics
Interleukin-12
Helper-Inducer T-Lymphocytes
Inflammatory Bowel Diseases
Pathology
Antibodies

Keywords

  • Anti-IL-12
  • Anti-IL-6R
  • Anti-TNF
  • Crohn's disease
  • Cytokines
  • IBD

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology

Cite this

Cytokine therapies in Crohn's disease : Where are we now and where should we go? / Caprioli, Flavio; Pallone, Francesco; Monteleone, Giovanni.

In: Inflammation and Allergy - Drug Targets, Vol. 10, No. 1, 2011, p. 47-53.

Research output: Contribution to journalArticle

@article{25e13f3d33234ac28ec4ca1a3ccef74b,
title = "Cytokine therapies in Crohn's disease: Where are we now and where should we go?",
abstract = "In the gut of patients with Crohn's disease (CD), one of the major forms of inflammatory bowel diseases in humans, distinct subsets of T helper (Th) cells produce large amounts of cytokines, which are supposed to orchestrate the immuno-inflammatory process leading to the tissue damage. Indeed, cytokine blockers, including the three licensed anti- TNF-α and the neutralizing IL-12/p40 antibodies, have already been tested with success in CD. More than one third of patients do not respond to these treatments and response can wane with time. Moreover, blockade of such cytokines has been reported to associate with development of severe side effects and/or new immune-mediated pathologies. These findings and our better understanding of cytokine-associated effector pathways of tissue destruction suggest the necessity of novel cytokine-based therapies in CD.",
keywords = "Anti-IL-12, Anti-IL-6R, Anti-TNF, Crohn's disease, Cytokines, IBD",
author = "Flavio Caprioli and Francesco Pallone and Giovanni Monteleone",
year = "2011",
language = "English",
volume = "10",
pages = "47--53",
journal = "Current Drug Targets: Inflammation and Allergy",
issn = "1871-5281",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Cytokine therapies in Crohn's disease

T2 - Where are we now and where should we go?

AU - Caprioli, Flavio

AU - Pallone, Francesco

AU - Monteleone, Giovanni

PY - 2011

Y1 - 2011

N2 - In the gut of patients with Crohn's disease (CD), one of the major forms of inflammatory bowel diseases in humans, distinct subsets of T helper (Th) cells produce large amounts of cytokines, which are supposed to orchestrate the immuno-inflammatory process leading to the tissue damage. Indeed, cytokine blockers, including the three licensed anti- TNF-α and the neutralizing IL-12/p40 antibodies, have already been tested with success in CD. More than one third of patients do not respond to these treatments and response can wane with time. Moreover, blockade of such cytokines has been reported to associate with development of severe side effects and/or new immune-mediated pathologies. These findings and our better understanding of cytokine-associated effector pathways of tissue destruction suggest the necessity of novel cytokine-based therapies in CD.

AB - In the gut of patients with Crohn's disease (CD), one of the major forms of inflammatory bowel diseases in humans, distinct subsets of T helper (Th) cells produce large amounts of cytokines, which are supposed to orchestrate the immuno-inflammatory process leading to the tissue damage. Indeed, cytokine blockers, including the three licensed anti- TNF-α and the neutralizing IL-12/p40 antibodies, have already been tested with success in CD. More than one third of patients do not respond to these treatments and response can wane with time. Moreover, blockade of such cytokines has been reported to associate with development of severe side effects and/or new immune-mediated pathologies. These findings and our better understanding of cytokine-associated effector pathways of tissue destruction suggest the necessity of novel cytokine-based therapies in CD.

KW - Anti-IL-12

KW - Anti-IL-6R

KW - Anti-TNF

KW - Crohn's disease

KW - Cytokines

KW - IBD

UR - http://www.scopus.com/inward/record.url?scp=79551619827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551619827&partnerID=8YFLogxK

M3 - Article

C2 - 21184652

AN - SCOPUS:79551619827

VL - 10

SP - 47

EP - 53

JO - Current Drug Targets: Inflammation and Allergy

JF - Current Drug Targets: Inflammation and Allergy

SN - 1871-5281

IS - 1

ER -